Remdesivir-Associated Survival Outcomes Among Immunocompromised Patients Hospitalized for COVID-19: Real-world Evidence From the Omicron-Dominant Era
Clinical Infectious Diseases · 2024
DOI: 10.1093/cid/ciae510 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Essy Mozaffari und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medical Affairs, Gilead Sciences, Foster City, California, USA. Hauptthemen laut MEDLINE: Alanine, Adenosine Monophosphate, Immunocompromised Host, COVID-19 Drug Treatment. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences.
Abstract (Originalsprache)
Background
Patients with immunocompromising conditions are at increased risk for coronavirus disease 2019 (COVID-19)–related hospitalizations and deaths. Randomized clinical trials provide limited enrollment, if any, to provide information on the outcomes in such patients treated with remdesivir.
Methods
Using the US PINC AI Healthcare Database, we identified adult patients with immunocompromising conditions, hospitalized for COVID-19 between December 2021 and February 2024. The primary outcome was all-cause inpatient mortality examined in propensity score–matched patients in remdesivir vs nonremdesivir groups. Subgroup analyses were performed for patients with cancer, hematological malignancies, and solid organ or hematopoietic stem cell transplant recipients.
Results
Of 28 966 patients included in the study, 16 730 (58%) received remdesivir during the first 2 days of hospitalization. After propensity score matching, 8822 patients in the remdesivir and 8822 patients in the nonremdesivir group were analyzed. Remdesivir was associated with a significantly lower mortality rate among patients with no supplemental oxygen (adjusted hazard ratio [95% confidence interval], 0.73 [.62–.86] at 14 days and 0.79 [.68–.91] at 28 days) and among those with supplemental oxygen (0.75 [.67–.85] and 0.78 [.70–.86], respectively). Remdesivir was also associated with lower mortality rates in subgroups of patients with cancer, hematological malignancies (leukemia, lymphoma, or multiple myeloma), and solid organ or hematopoietic stem cell transplants.
Conclusions
In this large cohort of patients with immunocompromising conditions hospitalized for COVID-19, remdesivir was associated with significant improvement in survival, including patients with varied underlying immunocompromising conditions. The integration of current real-world evidence into clinical guideline recommendations can inform clinical communities to optimize treatment decisions in the evolving COVID-19 era, extending beyond the conclusion of the public health emergency declaration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Affairs, Gilead Sciences, Foster City, California, USA.
- Evidence and Access, Certara, New York, New York, USA.
- Department of Internal Medicine, Baylor University Medical Center, Dallas, Texas, USA.
- Baylor Scott & White Heart and Vascular Hospital, Dallas, Texas, USA.
- Baylor Scott & White The Heart Hospital, Plano, Texas, USA.
- Baylor Scott & White Research Institute, Dallas, Texas, USA.
ORCID-Profile: Aastha Chandak, Robert L Gottlieb, Chidinma Chima-Melton, Mark Berry, Alpesh N Amin, Paul E Sax, Andre C Kalil
Förderung
- Gilead Sciences
Zitieren
APA
Mozaffari, E., Chandak, A., Gottlieb, R. L., Chima-Melton, C., Berry, M., Amin, A. N., Sax, P. E., & Kalil, A. C. (2024). Remdesivir-Associated Survival Outcomes Among Immunocompromised Patients Hospitalized for COVID-19: Real-world Evidence From the Omicron-Dominant Era. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae510
Vancouver
Mozaffari E, Chandak A, Gottlieb RL, Chima-Melton C, Berry M, Amin AN, et al. Remdesivir-Associated Survival Outcomes Among Immunocompromised Patients Hospitalized for COVID-19: Real-world Evidence From the Omicron-Dominant Era. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciae510
BibTeX
@article{Mozaffari2024,
author = {Mozaffari, Essy and Chandak, Aastha and Gottlieb, Robert L and Chima-Melton, Chidinma and Berry, Mark and Amin, Alpesh N and Sax, Paul E and Kalil, Andre C},
title = {Remdesivir-Associated Survival Outcomes Among Immunocompromised Patients Hospitalized for COVID-19: Real-world Evidence From the Omicron-Dominant Era},
journal = {Clinical Infectious Diseases},
year = {2024},
doi = {10.1093/cid/ciae510}
}
EUVIMED